📊 CTKB Key Takeaways
Is Cytek Biosciences, Inc. (CTKB) a Good Investment?
Cytek Biosciences operates an unprofitable business model with stagnant revenue growth (0.5% YoY) and severe operating losses (-41.8% margin), burning cash despite maintaining healthy 48.2% gross margins. While the fortress balance sheet (0.00x debt/equity, $65.7M cash) provides a multi-year runway, the lack of revenue traction and persistent operational losses suggest fundamental business model challenges that require immediate corrective action to avoid prolonged value destruction.
Cytek Biosciences shows a mixed fundamental profile: the company has strong gross margins, substantial liquidity, and almost no leverage, but revenue growth is essentially flat and profitability remains deeply negative. Cash burn is still relatively manageable versus its cash balance, yet the business needs clearer operating leverage and sustained improvement in margins to support a stronger fundamental outlook.
Cytek Biosciences, Inc. Key Strengths (CTKB)
- Gross margin of 48.2% demonstrates pricing power and product-market fit at the production level
- Minimal leverage (0.00x debt/equity ratio) and substantial equity cushion ($327.6M) mitigate bankruptcy risk
- Exceptional liquidity (4.69x current ratio, 4.07x quick ratio) provides 13+ years of operational runway at current burn rate
- Strong liquidity with a 5.04x current ratio and $90.85M in cash
- Healthy gross margin of 51.8%, indicating solid core product economics
- Very low leverage with only $525K of long-term debt and near-zero debt/equity
CTKB Stock Risks: Cytek Biosciences, Inc. Investment Risks
- Operating losses of -$18.5M on $44.1M revenue indicate severe cost structure misalignment and 90%+ operating expense ratio
- Revenue stagnation at 0.5% YoY growth signals lack of market demand, competitive disadvantage, or saturated addressable market
- Negative free cash flow (-$4.9M) demonstrates unsustainable business model despite positive gross profit, suggesting excessive R&D, SG&A, or capex
- Persistent net losses (-42.7% margin, -$18.9M net income) and negative returns (ROE -5.8%, ROA -4.2%) destroy shareholder value with no turnaround evidence
- Operating and net margins remain deeply negative at -20.0% and -33.0%
- Revenue growth of just 0.5% suggests weak growth quality and limited momentum
- Negative free cash flow and operating cash flow indicate the business is not yet self-funding
Key Metrics to Watch
- Operating margin trajectory and operating expense ratio (absolute reduction required to reach profitability)
- Revenue growth acceleration (0.5% YoY is terminal; need evidence of market expansion or new product adoption)
- Operating cash flow inflection (currently -$2.7M; must turn positive for business sustainability)
- Operating margin improvement
- Revenue growth acceleration
Cytek Biosciences, Inc. (CTKB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.69x current ratio provides a solid financial cushion.
CTKB Profit Margin, ROE & Profitability Analysis
CTKB vs Industrial Sector: How Cytek Biosciences, Inc. Compares
How Cytek Biosciences, Inc. compares to Industrial sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cytek Biosciences, Inc. Stock Overvalued? CTKB Valuation Analysis 2026
Based on fundamental analysis, Cytek Biosciences, Inc. has mixed fundamental signals relative to the Industrial sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cytek Biosciences, Inc. Balance Sheet: CTKB Debt, Cash & Liquidity
CTKB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cytek Biosciences, Inc.'s revenue has grown significantly by 57% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.00 indicates the company is currently unprofitable.
CTKB Revenue Growth, EPS Growth & YoY Performance
CTKB Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $41.5M | -$11.4M | $-0.09 |
| Q3 2025 | $51.5M | N/A | $0.01 |
| Q2 2025 | $45.6M | N/A | $-0.04 |
| Q1 2025 | $41.5M | -$6.2M | $-0.05 |
| Q3 2024 | $48.0M | N/A | $0.01 |
| Q2 2024 | $46.6M | N/A | $-0.03 |
| Q1 2024 | $37.1M | N/A | $-0.05 |
| Q3 2023 | $40.5M | N/A | $-0.01 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Cytek Biosciences, Inc. Dividends, Buybacks & Capital Allocation
CTKB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cytek Biosciences, Inc. (CIK: 0001831915)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CTKB
What is the AI rating for CTKB?
Cytek Biosciences, Inc. (CTKB) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 72% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CTKB's key strengths?
Claude: Gross margin of 48.2% demonstrates pricing power and product-market fit at the production level. Minimal leverage (0.00x debt/equity ratio) and substantial equity cushion ($327.6M) mitigate bankruptcy risk. ChatGPT: Strong liquidity with a 5.04x current ratio and $90.85M in cash. Healthy gross margin of 51.8%, indicating solid core product economics.
What are the risks of investing in CTKB?
Claude: Operating losses of -$18.5M on $44.1M revenue indicate severe cost structure misalignment and 90%+ operating expense ratio. Revenue stagnation at 0.5% YoY growth signals lack of market demand, competitive disadvantage, or saturated addressable market. ChatGPT: Operating and net margins remain deeply negative at -20.0% and -33.0%. Revenue growth of just 0.5% suggests weak growth quality and limited momentum.
What is CTKB's revenue and growth?
Cytek Biosciences, Inc. reported revenue of $44.1M.
Does CTKB pay dividends?
Cytek Biosciences, Inc. does not currently pay dividends.
Where can I find CTKB SEC filings?
Official SEC filings for Cytek Biosciences, Inc. (CIK: 0001831915) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CTKB's EPS?
Cytek Biosciences, Inc. has a diluted EPS of $-0.09.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CTKB's fundamental grade?
Based on our AI fundamental analysis in June 2026, Cytek Biosciences, Inc. has a C grade with 72% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CTKB stock overvalued or undervalued?
Valuation metrics for CTKB: ROE of -5.8% (sector avg: 15%), net margin of -42.7% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
What is CTKB's AI grade for 2026?
Our dual AI analysis gives Cytek Biosciences, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CTKB's free cash flow?
Cytek Biosciences, Inc.'s operating cash flow is $-2.7M, with capital expenditures of $2.2M. FCF margin is -11.1%.
How does CTKB compare to other Industrial stocks?
Vs Industrial sector averages: Net margin -42.7% (avg: 10%), ROE -5.8% (avg: 15%), current ratio 4.69 (avg: 1.8).